Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2007

View Archived Issues

Migenix reports preliminary interim results from phase II study of celgosivir for hepatitis C

New therapeutic option for pruritus reported in recent Janssen patent

GSK patent claims new pharmaceutically acceptable salts of sildenafil

Novel agents for treating diabetes disclosed in recent patent literature

KW-0761 investigated in phase I study in lymphoma patients

Stem cell transplant plus T-cells with bispecific antibody studied in lymphoma

ImmuneRegen and DelSite enter agreement to design and develop pandemic flu treatment

Preclinical studies shed light on the activity of ofatumumab in B-cells

Possible effect on survival seen with AL-02 in amyotrophic lateral sclerosis

KNS-760704 doses up to 300 mg safe in healthy volunteers

Recombinant DNA Advisory Committee reports its assessment of SAE in trial of tgAAC-94

Alizyme enters partnership and codevelopment agreement with TSD Japan for Colal-Pred

The Statens Serum Institut initiates phase I clinical trial of TB vaccine HyVac4-IC31

AVEO and Lilly sign agreement for clinical drug response project

Inhibiton's ICA-1 compound effective in in vitro testing in various cancer cell lines

Ipsogen undertakes pilot JAK2 cancer biomarker study with AstraZeneca

Phase II studies commence for Portola's novel antiplatelet agent, PRT-060128

Positive results reported for controlled-release rheumatology product, MIST-B04

Preliminary results of OvaRex ovarian cancer study fail to meet primary endpoint

SGX submits IND application to FDA for SGX-523

Newron initiates preclinical development of sodium channel blocker NW-3509

Myriad Genetics submits IND on Vivecon

Immtech Pharmaceuticals grants license to BioAlliance for pafuramidine maleate in Europe

Karo Bio initiates phase I clinical studies of KB-3305 for type 2 diabetes

FDA approves Medarex's two IND applications for MDX-1342 in CLL and arthritis

FDA Oncologic Drugs Advisory Committee rejects Genentech's Avastin for breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...